Benjamin F. Edwards & Company’s Jazz Pharmaceuticals JAZZ Stock Holding History

Benjamin F. Edwards & Company’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-391	Closed	-$69K	–	1737
2021 Q2	$69K	Buy	391 +94	+32%	+$16.3K	﹤0.01%	948
2021 Q1	$49K	Buy	297 +67	+29%	+$11K	﹤0.01%	1011
2020 Q4	$38K	Sell	230 -19	-8%	-$2.83K	﹤0.01%	1033
2020 Q3	$36K	Sell	249 -55	-18%	-$6.82K	﹤0.01%	977
2020 Q2	$34K	Buy	304 +87	+40%	+$9.62K	﹤0.01%	962
2020 Q1	$22K	Sell	217 -77	-26%	-$9.96K	﹤0.01%	1054
2019 Q4	$44K	Sell	294 -706	-71%	-$96.1K	﹤0.01%	1004
2019 Q3	$128K	Buy	+1,000	New	+$134K	0.01%	674
2019 Q1	–	Sell	-11	Closed	-$1K	–	1742
2018 Q4	$1K	Buy	+11	New	+$1.63K	﹤0.01%	1649
2016 Q1	–	Sell	-2	Closed	–	–	1150
2015 Q4	$0	Buy	+2	New	+$277	﹤0.01%	1200

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Benjamin F. Edwards & Company's JAZZ Position: Q3 2021 in Review

Benjamin F. Edwards & Company sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2021, closing a stake of 391 shares — an estimated $69K sold.

Benjamin F. Edwards & Company first reported a position in JAZZ in Q4 2015 and held it in 10 quarters. The position peaked at $128K in Q3 2019. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Benjamin F. Edwards & Company reported no remaining Jazz Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Benjamin F. Edwards & Company sold 391 Jazz Pharmaceuticals shares in Q3 2021, an estimated $69K.
Benjamin F. Edwards & Company first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 10 quarters.
Benjamin F. Edwards & Company's Jazz Pharmaceuticals position peaked at $128K in Q3 2019.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Benjamin F. Edwards & Company's 13F filing for Q3 2021, filed 2 Nov 2021.